Heparin – An old drug with multiple potential targets in Covid‐19 therapy
- 19 May 2020
- journal article
- letter
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 18 (9), 2422-2424
- https://doi.org/10.1111/jth.14898
Abstract
No abstract availableFunding Information
- Cancerfonden (CAN2018/541)
- Vetenskapsrådet
This publication has 10 references indexed in Scilit:
- The versatile heparin in COVID‐19Journal of Thrombosis and Haemostasis, 2020
- Non-Anticoagulant Heparins as Heparanase InhibitorsPublished by Springer Science and Business Media LLC ,2020
- The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical studyPublished by Cold Spring Harbor Laboratory ,2020
- Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathyJournal of Thrombosis and Haemostasis, 2020
- Disseminated intravascular coagulation in patients with 2019‐nCoV pneumoniaJournal of Thrombosis and Haemostasis, 2020
- The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin bindingPublished by Cold Spring Harbor Laboratory ,2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- The Role of Heparan Sulfate in Inflammation, and the Development of Biomimetics as Anti-Inflammatory StrategiesJournal of Histochemistry & Cytochemistry, 2018
- Chapter 3 Interactions Between Heparan Sulfate and Proteins—Design and Functional ImplicationsPublished by Elsevier BV ,2009
- Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.Proceedings of the National Academy of Sciences of the United States of America, 1980